<DOC>
	<DOCNO>NCT02263989</DOCNO>
	<brief_summary>Study investigate bioequivalence 40 mg telmisartan film-coated tablet vs. conventional 40 mg telmisartan tablet</brief_summary>
	<brief_title>Bioequivalence Telmisartan Film-coated Tablet Compared With Conventional Telmisartan Tablet Following Oral Administration Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Healthy male accord follow criterion : 1 . Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead ECG , clinical laboratory test No finding deviate normal clinical relevance No evidence clinically relevant concomitant disease 2 . Age ≥20 ≤35 year 3 . Body mass index ( BMI ) ≥17.6 ≤26.4 kg/m2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 3 . Chronic relevant acute infection 4 . Any clinical relevant finding laboratory test deviate normal 5 . Positive result either hepatitis B surface antigen ( HBs antigen ) , anti hepatitis C virus ( HCV ) antibody , syphilitic test human immunodeficiency virus ( HIV ) test 6 . History surgery gastrointestinal tract ( except appendectomy ) 7 . History relevant orthostatic hypotension ( mean stand systolic blood pressure ( SBP ) vary ≥20 mmHg mean supine SBP mean stand diastolic blood pressure ( DBP ) vary ≥10 mmHg mean supine DBP ) , faint spell blackouts 8 . History hepatic dysfunction ( e.g . biliary cirrhosis , cholestasis ) 9 . History serious renal dysfunction 10 . History bilateral renal artery stenosis renal artery stenosis solitary kidney 11 . History cerebrovascular disorder 12 . History hyperkalemia 13 . Known hypersensitivity component telmisartan formulation , angiotensin II receptor blocker ( ARBs ) 14 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 15 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 7 day prior administration trial 16 . Participation another trial investigational drug within 4 month 6 halflives investigational drug prior administration 17 . Smoker ( ≥20 cigarettes/day ) 18 . Alcohol abuse ( 60 g ethanol/day : ex . 3 middlesized bottle beer , 3 gous ( equivalent 540 mL ) sake ) 19 . Drug abuse 20 . Blood donation ( 100 mL within 4 week prior administration trial ) 21 . Excessive physical activity ( within 1 week prior administration trial ) 22 . Intake alcohol within 2 day prior administration 23 . Inability comply dietary regimen study centre 24 . Inability refrain smoke trial day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>